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Abstract
The genetic basis of myotonic dystrophy type I (DM1) is the expansion of a CTG tract located in the 39 untranslated region of
DMPK. Expression of mutant RNAs encoding expanded CUG repeats plays a central role in the development of cardiac
disease in DM1. Expanded CUG tracts form both nuclear and cytoplasmic aggregates, yet the relative significance of such
aggregates in eliciting DM1 pathology is unclear. To test the pathophysiology of CUG repeat encoding RNAs, we developed
and analyzed mice with cardiac-specific expression of a beta-galactosidase cassette in which a (CTG)400 repeat tract was
positioned 39 of the termination codon and 59 of the bovine growth hormone polyadenylation signal. In these animals CUG
aggregates form exclusively in the cytoplasm of cardiac cells. A key pathological consequence of expanded CUG repeat RNA
expression in DM1 is aberrant RNA splicing. Abnormal splicing results from the functional inactivation of MBNL1, which is
hypothesized to occur due to MBNL1 sequestration in CUG foci or from elevated levels of CUG-BP1. We therefore tested the
ability of cytoplasmic CUG foci to elicit these changes. Aggregation of CUG RNAs within the cytoplasm results both in Mbnl1
sequestration and in approximately a two fold increase in both nuclear and cytoplasmic Cug-bp1 levels. Significantly,
despite these changes RNA splice defects were not observed and functional analysis revealed only subtle cardiac
dysfunction, characterized by conduction defects that primarily manifest under anesthesia. Using a human myoblast culture
system we show that this transgene, when expressed at similar levels to a second transgene, which encodes expanded CTG
tracts and facilitates both nuclear focus formation and aberrant splicing, does not elicit aberrant splicing. Thus the lack of
toxicity of cytoplasmic CUG foci does not appear to be a consequence of low expression levels. Our results therefore
demonstrate that the cellular location of CUG RNA aggregates is an important variable that influences toxicity and support
the hypothesis that small molecules that increase the rate of transport of the mutant DMPK RNA from the nucleus into the
cytoplasm may significantly improve DM1 pathology.
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Introduction
Myotonic dystrophy 1 (DM1) is a multi-system disorder
characterized by skeletal myopathy and cardiac disease [1].
Sudden cardiac failure is one of the main causes of death in
DM1 patients. Cardiac symptoms include variable conduction
disorders and wall motion abnormalities [2–6]. First degree
atrioventricular (AV) block and intraventricular conduction
disorders are seen in ,75% of DM1 patients [2]. Progressive
deterioration of the conduction system resulting in complete AV
block or ventricular arrhythmias are primarily responsible for
sudden cardiac death [3,4]. Although conduction disorders
predominate in DM1, decreased ventricular systolic and diastolic
functions, and hypertrophic and dilated cardiomyopathy, have
been reported in severely affected patients [5–8]. Histological
abnormalities include myofibrillar loss, fibrosis and fatty infiltra-
tion of both the working myocardium and the specialized
conduction system. Electron microscopic examination shows
aberrant Z lines and mitochondrial abnormalities in DM1 hearts
[9].
The genetic defect in DM1 is the expansion of a CTG repeat
tract on chromosome 19q13.3. The repeat expansion is located in
the 39 untranslated region of a protein kinase gene, DMPK, and is
found 59 of a homeodomain-encoding gene, SIX5 [10–13]. CTG
tract size is a strong predictor of cardiac involvement, particularly
for electrocardiographic conduction, and wall motion abnormal-
ities. Small expansions of 50–100 repeats produce a mild form of
DM1 characterized primarily by the development of cataracts late
in adult life. A multi-system adult onset form of the disease
manifesting with cardiac disease occurs in a range of 250–500
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repeats. Progressive increase in CTG tract size, to lengths greater
than 1500 repeats, results in increased incidence and severity of
the cardiac phenotype [4,5]. Three non-exclusive molecular
defects hypothesized to contribute to DM1 pathology are (i)
decreased DMPK levels resulting from aberrant nuclear accumu-
lation of the mutant DMPK RNA [14,15] (ii) decreased SIX5 levels
occurring as a consequence of chromatin condensation that occurs
in the vicinity of the expanded CTG tract [16–18] and (iii) intrinsic
toxicity of the expanded CUG tracts [19].
We have previously shown that both Dmpk+/2 and Dmpk2/2
mice demonstrate PR prolongation or first degree heart block,
while Dmpk2/2 mice exhibit a more severe phenotype consisting of
both second and third degree heart block [20–22]. However,
histological defects and wall motion abnormalities are not detected
in these animals and the life-span of wild-type and mutant Dmpk
mice is not significantly different. Structure-function analysis of
Six5+/2 cardiac muscle demonstrates that reduced Six5 levels
result in mild infra-Hisian conduction delay, increased left
ventricular end diastolic dimension, and ventricular hypertrophy
[23]. As reduction in Dmpk and Six5 levels does not completely
recapitulate the severity of DM1 cardiac pathology, these data
suggest that toxic effects associated with the expression of CUG
repeats play a prominent role in the etiology of DM1 heart disease.
Consistent with a key role for expanded CUG repeat RNA in
DM1 cardiac pathophysiology, inducible expression of high levels
,960 interrupted CTG repeats located in the DMPK 39UTR
results in arrhythmias and cardiomyopathy that often lead to
death of the transgenic animals within a few weeks after induction
of the transgene [24]. In these experiments both elevated Cug-bp1
levels and aggregation of Mbnl1 in intra-nuclear RNA foci are
documented in conjunction with aberrant splice site selection in a
set of physiologically important RNAs [24]. Thus, as expression of
expanded CUG repeats elicits key features of DM1 cardiac
pathology, therapeutic strategies will require identification of
mechanisms that will allow such RNAs to be rendered inert.
Here, we demonstrate that the cellular location of CUG RNA
aggregates is a variable that influences the development and severity
of DM1 cardiac pathology. In this study, we developed transgenic
mice with cardiac-specific expression of a b-galactosidase cassette in
which a (CTG)400 repeat tract is located 39 of the termination codon
of the b-galactosidase gene and 59 of the bovine growth hormone
poly A sequence. In these animals RNAs encoding expanded CUG
repeats were found to aggregate exclusively within the cytoplasm of
cardiomyocytes. Both in DM1 cells and in transgenic mice
demonstrating cardiac specific expression of expanded CTG tracts
located in the DMPK 39UTR, aberrant RNA splicing is observed in
conjunction with the aggregation of Mbnl1 in the nuclear CUG foci
and increased steady-state levels of Cug-bp1 [24–26]. We therefore
tested the ability of cytoplasmic CUG foci to elicit these changes. We
observe both sequestration of Mbnl1 in the cytoplasmic CUG
aggregates and approximately a two-fold elevation in the levels of
Cug-bp1 in cardiomyocytes. Importantly, these defects did not result
in abnormal RNA splicing and caused only a mild cardiac
pathology, which manifests primarily as conduction defects under
anesthesia. These results demonstrate that (i) CTG tracts expressed
in a context independent manner can elicit elevated Cug-bp1 levels,
(ii) a two fold elevation of Cug-bp1 levels is insufficient to dysregulate
splice site choice in the adult mouse heart and (iii) aggregation of
Mbnl1 in CUG foci per se may not be sufficient to inactivate Mbnl1.
The relative lack of toxicity of cytoplasmic CUG RNA
aggregates is unlikely to be a consequence of low expression
levels, as an independent set of experiments carried out in human
myoblasts demonstrate that when this transgene is expressed at
similar levels to a second transgene in which the expanded CTG
tract was expressed in the context of the DMPK 39UTR, it is
unable to dysregulate RNA splicing. Consistent with our study,
previous experiments in mouse myoblast cultures demonstrate that
CTG tracts expressed in the context of the DMPK 39UTR are no
longer able to dysregulate myoblast differentiation when this
cassette was re-engineered to encode the woodchuck post
transcriptional element that served to localize the CUG encoding
RNA within the cytoplasm [27]. These data therefore demonstrate
that when expanded CUG tracts, expressed in a context
independent manner or in the context of the DMPK 39UTR,
localize in the cytoplasm, they are unable to cause aberrant RNA
splicing or significant pathology, when assessed in myoblast
cultures or in the context of the adult mouse. Thus our data
support the therapeutic use of small molecules that increase the
transport of the mutant DMPK RNA from the nucleus into the
cytoplasm as a means of greatly ameliorating DM1 pathology in
vivo.
Results
DM1 myoblasts and fibroblasts contain both nuclear and
cytoplasmic CUG foci
Both primary cultures and SV40 transformed DM1 fibroblasts
and myoblasts show CUG RNA foci in the nucleus and cytoplasm
[Figure 1 and Supplementary Figure S1 (Panels A–E)]. SV40
transformation does not significantly alter the localization of CUG
foci, as the percent of DM1 fibroblasts, which contain both nuclear
and cytoplasmic foci, did not vary appreciably in untreated
cultures and in SV40 immortalized lines [Figure 1; Table 1].
Construction and analyses of a-MHC-LacZ-(CTG)400 mice
To characterize the pathological effects intrinsic to the
expression of expanded CTG repeat tracts in cardiac muscle, we
built a transgenic cassette encoding the gene for b-galactosidase
(LacZ) followed by a tract of ,400 uninterrupted CTG repeats,
which was cloned in a linker sequence and inserted between the
LacZ termination codon and the bovine growth hormone
polyadenylation (BGH-PolyA) sequence. A 5.5 kb a-myosin heavy
chain (a-MHC) promoter, which encodes the first three untrans-
lated exons of a-MHC, was used to drive specific expression of the
LacZ-(CTG)400 cassette in the myocardium of embryonic atria
and in adult mouse atria and ventricles [28, Figure 2; Panel A].
Consistent with the instability, which characterizes uninterrupted
CTG tracts [29,30], the (CTG)400 repeats tract showed a marked
propensity to either delete or decrease in length when the plasmid
encoding the transgenic cassette was propagated in bacteria at
37uC [Figure 2; Panel B]. The CTG tract was mutation-free when
sequenced from each end to a distance of ,300 bp, after which
significant compressions were observed.
a-MHC-LacZ-(CTG)400 cassettes were injected into fertilized
C57BL/6J mouse eggs to generate two independent lines. A a-
MHC-LacZ cassette with no CTG tracts [a-MHC-LacZ-(CTG)0]
was injected in parallel to develop control lines. Southern blot
analyses of tail clip DNA from the progeny of both a-MHC-LacZ-
(CTG)400 founders derived after approximately one year of
breeding are shown in Figure 2; Panel C. Comparison of the
two a-MHC-LacZ-(CTG)400 lines demonstrate that the lines
showed deletions which ranged in length from ,50–70 and
,150–170 CTG repeats. However the majority of the CTG tracts
contained ,300–380 repeats with a significant fraction showing
expansions that occurred primarily to lengths of ,700–730 and
,800 CTG repeats.
Consistent with the average CTG tract sizes observed in the
transgenic mice, analysis of RNA isolated from hearts of a-MHC-
Cytoplasmic CUG RNA Foci
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LacZ mice and a-MHC-LacZ-(CTG)400 mice by Northern blots,
showed transcript sizes of ,3 and ,4.2 kb when probed with b-
galactosidase sequences [Figure 2; Panel D]. Progeny from the two
founder a-MHC-LacZ-(CTG)400 lines, demonstrate different
levels of LacZ-(CUG)400 RNA and are therefore denoted as a-
MHC-LacZ-(CTG)400TG
high and a-MHC-LacZ-(CTG)400TG
low
in the text.
Mbnl1 sequesters in cytoplasmic CUG RNA foci in a-MHC-
LacZ-(CTG)400 cardiomyocytes
To examine the behavior of LacZ-(CUG)400 RNAs, we isolated
cardiomyocytes from transgenic hearts and used fluorescence in
situ hybridization (FISH) to visualize the location of the expanded
CUG tracts with Cy3 labeled CAG probes [Figure 3]. CUG
repeat RNAs aggregate exclusively within the cytoplasm and are
excluded from the nucleus in a-MHC-LacZ-(CTG)400 cardiomy-
ocyte preparations. Similarly, CUG RNA foci were also detected
primarily in the cytoplasm when frozen tissue sections of in a-
MHC-LacZ-(CTG)400 mice were examined [Figure 3; Panels A &
B, .400 cells were examined in both a-MHC-LacZ-(CTG)400
cardiomyocyte preparations and in a-MHC-LacZ-(CTG)400
cardiac sections]. In these studies we observed that the cytoplasmic
foci had diffuse borders when compared to the foci detected in
DM1 cells.
Figure 1. DM1 fibroblasts and myoblasts contain both nuclear and cytoplasmic CUG foci. Panel A: Nuclear DAPI staining of normal and
DM1 fibroblasts and myoblasts, either untreated or immortalized with SV40, are shown in Panels a, d, g, j, m, p, s & v. DMPK transcripts encoding the
expanded CUG tracts were detected by hybridization with a (CAG)10-Cy3 probe (red signal; Panels h, k, n, q, t & w). Transcripts containing expanded
CUG repeats are not observed in the normal fibroblasts and normal myoblasts (b & e), respectively. Merged images of DAPI and (CAG)10-Cy3 stains
show CUG RNA foci as red signals (i, l, o, r, u & x) within the nucleus and in the cytoplasm in DM1 fibroblasts and myoblasts. The percent of DM1
fibroblasts and myoblasts containing both nuclear and cytoplasmic foci are tabulated in Table 1. Images of CUG RNA foci in additional DM1
fibroblasts and myoblasts are shown in supplementary Figure S1 (Panels A–E).
doi:10.1371/journal.pone.0003968.g001
Table 1. DM1 fibroblasts and myoblasts contain both nuclear and cytoplasmic CUG foci.
Cell type
SV40
immortalized
Total
cell #
# of cells containing
nuclear foci
# of cells containing both
nuclear and cytoplasmic foci
DM1 fibroblasts (CTG)333 2 97 65 32 (32.9%)
DM1 fibroblasts (CTG)333 + 68 45 23 (33.82%)
DM1 fibroblasts (CTG)667 2 134 93 41 (30.59%)
DM1 fibroblasts (CTG)667 + 77 53 24 (31.16%)
DM1 myoblasts (CTG)2860 + 196 125 71 (36.22%)
DM1 myoblasts (CTG)2800 + 86 57 29 (33.72%)
doi:10.1371/journal.pone.0003968.t001
Cytoplasmic CUG RNA Foci
PLoS ONE | www.plosone.org 3 December 2008 | Volume 3 | Issue 12 | e3968
To test if CUG-RNA aggregates aberrantly sequester the
alternative splice factor, Mbnl1, we stained both a-MHC-LacZ
and a-MHC-LacZ-(CTG)400 cardiomyocytes and normal hu-
man and DM1 myoblasts with anti-MBNL1 (MB1a) monoclonal
antibodies [31]. Co-localization studies demonstrate that Mbnl1
aberrantly sequesters within the cytoplasmic CUG RNA foci in
a-MHC-LacZ-(CTG)400 cardiomyocytes [Figure 4; Panel A].
Quantitation of the sequestered Mbnl1 demonstrates that the
percent of Mbnl1 sequestered in the cytoplasmic foci in a-
MHC-LacZ-(CTG)400 cardiomyocytes is not significantly dif-
ferent (6.65%) from the percent of MBNL1 sequestered within
the nuclear and cytoplasmic foci in DM1 myoblasts (8.01%)
[p = 0.37, Figure 4; Panel B & Table 2]. The specificity of
MBNL1 (MB1a) monoclonal antibody was verified by immu-
nofluorescence using cardiomyocytes derived from Mbnl12/2
mice [32, Supplementary Figure S2]. Thus these results
demonstrate that cytoplasmic CUG foci, although more diffuse
in appearance, can effectively sequester Mbnl1 in vivo.
Cug-bp1 levels are elevated in a-MHC-LacZ-(CTG)400
cardiomyocytes
To test if expression of LacZ-(CUG)400 RNAs can elicit a
change in steady-state Cug-bp1 levels, we measured the steady-
state levels of Cug-bp1 in tissue lysates derived from hearts of 6
months old a-MHC-LacZ-(CTG)400TG
high, a-MHC-LacZ-
(CTG)400TG
low and a-MHC-LacZ mice. Three independent
western blot analyses in which hearts from two mice of each
genotype were analyzed demonstrate a ,2.5 fold increase in Cug-
bp1 levels in a-MHC-LacZ-(CTG)400TG
high and ,1.6 fold
increase in a-MHC-LacZ-(CTG)400TG
low mice. The fold changes
in steady-state Cug-bp1 levels were not significantly different when
either 6 mg or 10 mg of proteins were sampled [Figure 5; Panel A].
In these experiments no significant alteration in steady-state
Mbnl1 levels were detected in a-MHC-LacZ and a-MHC-LacZ-
(CTG)400TG
high mice [Figure 5; Panel B]. To test if nuclear Cug-
bp1 levels were altered in a-MHC-LacZ-(CTG)400 mice, we
measured Cug-bp1 protein levels in the cytoplasmic and nuclear
Figure 2. Characterization of a-MHC-LacZ-(CTG)400 mice. Panel A: The a-MHC-LacZ-(CTG)400 transgene encoding the a-myosin heavy chain
promoter (a-MHC) used to drive cardiac specific expression of the b-galactosidase (LacZ) gene followed by a CTG tract of ,400 repeats and the
bovine growth hormone polyA (BGH-PolyA) sequence is shown. Panel B: Restriction digestion of plasmids encoding the a-MHC-LacZ-(CTG)400
sequences with SfiI, which allows excision of the CTG repeat tract, demonstrates the instability of the CTG repeats when propagated in E. coli at 37uC.
Panel C: Southern blot analysis of mouse tail-clip DNA digested with PvuII. The 280 bp probe used for hybridization (Panel A) is shown. The majority
of the detected bands contained 350,380 CTG repeats in a-MHC-LacZ-(CTG)400TGhigh (band intensities ,76%) or 300,350 CTG repeats in a-MHC-
LacZ-(CTG)400TG
low (band intensities,80%) in tail clip DNAs. Panel D: Northern blot analysis of RNA derived from a-MHC-LacZ-(CTG)400 and a-MHC-
LacZ mouse hearts probed with b-galactosidase and Gapdh sequences is shown.
doi:10.1371/journal.pone.0003968.g002
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fractions of heart tissue derived from a-MHC-LacZ, a-MHC-
LacZ-(CTG)400TG
high, and a-MHC-LacZ-(CTG)400TG
low ani-
mals. In these experiments Cug-bp1 was found to localize
primarily in the cytoplasm in both a-MHC-LacZ and a-MHC-
LacZ-(CTG)400 mice. Cug-bp1 levels were elevated ,2.7 and
,2.4 fold , and ,1.6 and ,1.2 fold in the cytoplasm and in the
nucleus of MHC-LacZ-(CTG)400TG
high and a-MHC-LacZ-
(CTG)400TG
low mice when compared to controls [Figure 5; Panel
C].
RNA splicing is not dysregulated in a-MHC-LacZ-(CTG)400
hearts
As the cytoplasmic LacZ-CUG foci aggregate Mbnl1 and elicit
elevated steady-state levels of Cug-bp1, we studied the effect of
LacZ-(CUG)400 RNA expression on RNA splice site choice. We
examined the pattern of alternative splicing of cardiac troponin T
(Tnnt2), Z-band alternatively spliced PDZ-motif protein (Zasp),
alpha-actinine-2 associated LIM protein (Alp) and M-line Titin (m-
Ttn) [33-35] RNAs. These RNAs are aberrantly spliced in adult
DM1 hearts and retain the pattern of splicing observed in new-
borns [36]. No significant change in the splicing pattern of these
RNAs is observed in heart tissue of either the a-MHC-LacZ-
(CTG)400TG
high or a-MHC-LacZ-(CTG)400TG
low mice when
compared to control a-MHC-LacZ mice. In all cases, the relative
percentages of the detected isoforms for each gene did not vary
significantly for each of the two amplification conditions tested
[Figure 6 & Table 3].
Expression of LacZ-(CUG)400 RNAs at levels equivalent to
that of a DMPK mini gene encoding 300 CTG repeats
does not result in aberrant RNA splicing in human
myoblasts
To examine if low expression levels are responsible for the lack
of toxicity of LacZ-(CUG)400 RNAs in a-MHC-LacZ-(CTG)400
mice, we studied a set of expression vectors in human myoblast
cultures in which the cytomegalovirus (CMV) promoter was used
to express cassettes encoding a DMPK minigene encoding either 5
or 300 interrupted CTG repeats [DMPK 11-15(CTG)5 or 300], the
Figure 3. CUG foci form exclusively in the cytoplasm of a-MHC-LacZ-(CTG)400 cardiomyocytes. Panel A: Nuclear DAPI staining of
cardiomyocytes derived from a-MHC-LacZ, a-MHC-LacZ-(CTG)400 mice and normal human and DM1 myoblasts is shown. Transcripts encoding the
expanded CUG tracts were detected by hybridization with a (CAG)10-Cy3 probe (red signal). CUG foci are observed in the cytoplasm in a-MHC-LacZ-
(CTG)400 cardiomyocytes (b, c) and in both the cytoplasm and nucleus of DM1 myoblasts (e) (1206magnification). Panel B: Nuclear DAPI staining of
heart sections of a-MHC-LacZ, a-MHC-LacZ-(CTG)400TG
high, and a-MHC-LacZ-(CTG)400TG
low are shown. CUG foci are observed in the cytoplasm of both
a-MHC-LacZ-(CTG)400TG
high, and a-MHC-LacZ-(CTG)400TG
low heart tissue sections [red signals; e, f (406magnification) and h, i (1206magnification)].
Transcripts containing expanded repeats are not observed in cardiomyocytes and heart sections of a-MHC-LacZ mice and in normal human
myoblasts [Panel A; a, d and Panel B; d, g]. .400 cells were examined in both a-MHC-LacZ-(CTG)400 cardiomyocyte preparations and in a-MHC-
LacZ-(CTG)400 cardiac sections.
doi:10.1371/journal.pone.0003968.g003
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green fluorescent protein linked to the DMPK 39UTR containing
either 5 or 400 CTG repeats [GFP-DMPK 39UTR(CTG)5 or 400],
or the b-galactosidase gene containing no repeats or 400 repeats
[LacZ-(CTG)0 or 400] [Figure 7; Panel A]. Expression of constructs
encoding both the DMPK 11-15 minigene and GFP-DMPK
39UTR with the expanded CTG repeats resulted in nuclear foci
and aberrant RNA splicing. All constructs that did not contain the
expanded CTG tracts did not dysregulate RNA splicing.
Expression of the LacZ-(CTG)400 construct formed cytoplasmic
CUG foci but did not alter splice site selection in IR and cTNT
RNAs [Figure 7; Panels B–C and Table 4]. RT-PCR analyses of
the steady-state expression levels of the b-galactosidase cassette
encoding 400 CTG tracts and the DMPK minigene encoding 300
CTG repeats, which are approximately 4.3 and 2.2 kb in length
Figure 4. Mbnl1 co-localizes with cytoplasmic CUG-foci in a-MHC-LacZ-(CTG)400 cardiomyocytes. Panel A: Distribution of endogenous
Mbnl1 is visualized as a green signal (a, d, g & j) using anti-MBNL1 (MB1a) monoclonal antibody and secondary antibodies conjugated with FITC. The
mutant transcripts encoding the expanded CUG tracts were detected by hybridization with a (CAG)10-Cy3 probe (red signals; e & h). Transcripts
containing expanded CUG repeats are not observed in the a-MHC-LacZ cardiomyocytes (b) and normal myoblasts (k). Merged images (f & i), where
super-imposition of green and red signals are observed as a yellow signals, show that Mbnl1 co-localizes with the expanded CUG tracts in the a-MHC-
LacZ-(CUG)400 cardiomyocytes (f) and in DM1 myoblasts (i). Panel B: Graphical representation of Mbnl1 distribution in each compartment (nucleus,
cytoplasm and foci) of a-MHC-LacZ, a-MHC-LacZ-(CUG)400 cardiomyocytes and DM1 and normal myoblasts is shown and the results are tabulated in
Table 2. No significant difference is observed in the fraction of Mbnl1 which colocalizes with the foci in a-MHC-LacZ-(CTG)400 cardiomyocytes and in
DM1 myoblasts (p = 0.37). The specificity of MBNL1 (MB1a) monoclonal antibody was assessed by immunofluorescence using cardiomyocytes derived
from Mbnl12/2 mice (Supplementary Figure S2).
doi:10.1371/journal.pone.0003968.g004
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respectively, demonstrate that the expression levels achieved by these
cassettes was not significantly different [p = 0.479, Figure 8; Panels
A–B and Table 5]. To further confirm that comparable expression
levels of LacZ-(CUG)400, and DMPK 11-15(CUG)300 RNAs were
assayed in these experiments, we quantitated the amounts of LacZ-
(CTG)400, and DMPK 11-15(CTG)300 cDNAs by Real-time PCR
analyses. Use of a standard curve generated from plasmid DNAs
encoding these sequences demonstrates that the steady-state
expression levels of the LacZ-(CTG)400, and DMPK 11-
15(CTG)300 cDNAs are similar [LacZ-(CTG)400 = 5.68610
24
fmoles and DMPK 11-15(CTG)300 = 4.17610
24 fmoles; Figure 8;
Panels C–F and Table 6]. Thus when expressed at a comparable
level to the DMPK minigene encoding 300 CTG repeats [DMPK
11-15(CUG)300], the LacZ-(CUG)400 RNAs are unable to dysregu-
late splicing in human myoblasts.
Electrocardiography demonstrates intraventricular
conduction defects in sedated a-MHC-LacZ-(CTG)400
mice
To test if cytoplasmic LacZ-CUG aggregates cause functional
defects in the heart, we carried out a series of in vivo experiments.
Surface 6-lead ECG and ambulatory telemetric ECG recordings
were performed in 14 a-MHC-LacZ-(CTG)400TG
high, 9 a-MHC-
LacZ-(CTG)400TG
low and 5 a-MHC-LacZ mice. PR intervals are
not prolonged in a-MHC-LacZ-(CTG)400TG
high and a-MHC-
LacZ-(CTG)400TG
low when compared to a-MHC-LacZ mice. P
wave amplitude and duration are quantitatively similar between
groups (data not shown). ECG data from sedated animals however
demonstrated prolonged QRS intervals in a-MHC-LacZ-
(CTG)400TG
low compared to a-MHC-LacZ-(CTG)400TG
high mice
and longer QT/QTc durations in a-MHC-LacZ-(CTG)400TG
low
compared to a-MHC-LacZ-(CTG)400TG
high and a-MHC-LacZ
mice. Intraventricular conduction delay or a bundle branch block
pattern was noticed in 6 of 9 a-MHC-LacZ-(CTG)400TG
low, 6 of
14 a-MHC-LacZ-(CTG)400TG
high mice, compared with 0 of 5 a-
MHC-LacZ mice (p = 0.054, Pearson Chi-Square). The ECG
measurements and calculations for all animals studied are
summarized in Tables 7 and 8.
Exercise Tolerance Testing did not elicit cardiac
arrhythmia
Exercise tolerance testing was accomplished in 14 of a-MHC-
LacZ-(CTG)400TG
high, 9 of a-MHC-LacZ-(CTG)400TG
low and 5
of a-MHC-LacZ mice. All 28 mice successfully completed
30 minutes of running. The PR intervals did not change
significantly during exercise testing, and no higher AV block or
any arrhythmias were provoked with exertion.
Mitochondrial defects are observed a-MHC-LacZ-(CTG)400
heart tissue
No gross abnormalities in the cardiac muscle structure were
observed in H & E sections of a-MHC-LacZ-(CTG)400 mice (data
not shown). Electron microscopy showed disarrayed cristae in
mitochondria in some sections of both adult a-MHC-LacZ-
(CTG)400TG
high and a-MHC-LacZ-(CTG)400TG
low mice but not
in a-MHC-LacZ mice [Figure 9]. Thus consistent with the lack of
RNA splice defects in a-MHC-LacZ-(CTG)400 mice, these results
demonstrate that LacZ-(CUG)400 RNAs are unable to elicit
significant cardiac pathology in vivo.
Discussion
Myotonic dystrophy is a multi-system disorder, characterized by
aberrant RNA splicing, which results from the expansion of a
CTG tract located in the 39UTR of DMPK. An important
mediator of DM1 pathology is the mutant DMPK RNA encoding
the expanded CUG tracts [24,37–39]. Thus a central aspect of
designing therapeutic interventions for this disease is to determine
how to alter such toxic RNAs into benign or relatively inert
macromolecules. RNAs encoding expanded CUG repeats form
both nuclear and cytoplasmic aggregates or foci in DM1 cells. The
relative toxicity of such aggregates both in terms of evoking
aberrant RNA splicing and in eliciting DM1 pathophysiology in
vivo is currently unknown. In this study we describe the behavior of
expanded CTG tracts expressed in the context of the b-
galactosidase gene under the control of the a-myosin heavy chain
promoter in mouse hearts. LacZ-(CUG)400 RNAs form aggregates
exclusively in the cytoplasm of cardiomyocytes in transgenic mice.
Significantly, the cytoplasmic LacZ-CUG RNA aggregates are
unable to dysregulate splice site choice in mouse hearts and result
only in mild cardiac dysfunction. Our results therefore support a
therapeutic strategy aimed at the identification of small molecules
that facilitate effective and rapid transport of toxic CUG RNAs
from the nucleus into the cytoplasm as a means of markedly
reducing the toxicity of such RNAs.
Several lines of evidence demonstrate that mutant RNAs
encoding expanded CUG repeat tracts embedded in the DMPK
39UTR, which aggregate within the nucleus, facilitate the
development of DM1 pathology. Seznec and colleagues have
shown that expression of expanded CTG tracts in the context of
the human DMPK gene results both in nuclear foci and the
development of DM1 pathology in mice [38]. In this study, the
severity of the phenotype was influenced both by tract size and
expression levels. Specifically, 300 CUG repeats were found to be
the minimum repeat tract length at which an overt pathology was
detected in mice. Transgene expression levels were a second
variable in this study, as homozygous animals were more severely
Table 2. Distribution of MBNL1 in a-MHC-LacZ-(CTG)400 cardiomyocytes and DM1 myoblasts.
Cell type Cell # % MBNL1 p-value (Foci)
Nuclus Cytoplasm Foci
a-MHC-LacZ cardiomyocytes 8 59.0265.46 40.9765.46 0.0
a-MHC-LacZ-(CTG)400TG
high cardiomyocytes 20 57.81611.35 35.5369.32 6.6563.06#
DM1 myoblasts 18 71.54611.45 20.43610.49 8.0163.19# 0.37
Normal myoblasts 16 63.1467.43 36.8667.43 0.0
(#)represents pair wise comparison; p-value (Student’s t-test) denotes no significant difference in MBNL1 sequestered in foci of a-MHC-LacZ-(CTG)400TG
high and DM1
myoblasts.
doi:10.1371/journal.pone.0003968.t002
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affected than hemizygous mice. Nonetheless, not all of the animals
that expressed CUG foci in the nucleus demonstrate a DM1
phenotype. Such differences were attributed by the authors to
possible variations in the pattern of transgene expression during
development or differences in RNA stability [38]. Consistent with
these earlier results, inducible expression of high levels of
interrupted CUG repeat tracts expressed in the context of the
DMPK 39UTR, under the control of a strong ubiquitous
promoter, has also been shown to result in the rapid aggregation
of CUG repeats within the nucleus and the development of severe
Figure 6. Aberrant splicing is not observed in a-MHC-LacZ-(CTG)400 hearts. Total RNA isolated from adult a-MHC-LacZ-(CTG)400 and adult a-
MHC-LacZ hearts and wild-type postnatal day1 and day 2 mouse hearts was subjected to RT-PCR analysis using the Tnnt2, Alp, Zasp and m-Ttn
primers as described in Methods. Gapdh RNA was amplified in parallel as an internal control. The experiments were carried out in triplicate and the
results are tabulated in Table 3.
doi:10.1371/journal.pone.0003968.g006
Table 3. Alternative RNA splicing in a-MHC-LacZ-(CTG)400 hearts.
Gene Accession no.
Alt. spliced exon
number n % Exons inclusion
WT adult LacZ adult TGhigh adult Tglow adult
WT Posnatal day
1
WT Posnatal day
2
Tnnt2 NM_011619 5 3 6.861.15 6.1561.1 6.961.3 7.560.9 24.361.7* 22.261.6*
Alp AF002283 5a 3 81.762.0 80.261.6 80.561.8 81.162.5 98.260.5* 97.761.0*
Zasp AY206013 11 3 67.964.7 65.563.1 67.664.1 69.165.3 91.660.7* 89.761.3*
m-Ttn XM_130312 Mex5 3 48.761.2 47.661.3 48.261.3 47.460.9 98.660.4* 98.460.5*
Asterisk (*) represents significant differences from wild type (WT) adult (Student’s t-test; p,0.05). Tnnt2, cardiac troponin T; Alp, alpha-actinine-2 associated LIM protein;
Zasp, Z-band alternatively spliced PDZ-motif protein; m-Ttn, M-line Titin; LacZ, a-MHC-LacZ-(CTG)0; TG
high, a-MHC-LacZ-(CTG)400TG
high; TGlow, a-MHC-LacZ-
(CTG)400TG
low.
doi:10.1371/journal.pone.0003968.t003
Figure 5. a-MHC-LacZ-(CTG)400 mice show increased steady-state levels of Cug-bp1. Panels A–B: Protein extracts were prepared from a-
MHC-LacZ, a-MHC-LacZ-(CTG)400TG
high, and a-MHC-LacZ-(CTG)400TG
low mouse hearts and 6 or 10 mg of the total proteins from the tissue extracts
were resolved on SDS-PAGE followed by Western blot analyses and immunostaining with CUG-BP1 and MBNL1 monoclonal antibodies (mAb),
respectively. The blots were re-probed for GAPDH using anti-GAPDH polyclonal antibodies as an internal control. The experiments were carried out in
triplicate and mean values of steady-state Cug-bp1 and Mbnl1 levels are shown. Panel C: Cytoplasmic and nuclear proteins extracts (10 mg) from a-
MHC-LacZ, a-MHC-LacZ-(CTG)400TG
high, and a-MHC-LacZ-(CTG)400TG
low mouse hearts were resolved on SDS-PAGE followed by Western blot analyses
and immunostaining with CUG-BP1 mAb. The blots were re-probed for TATA binding protein (TBP), and for GAPDH, which were used as nuclear and
cytoplasmic markers respectively. The experiments were carried out in triplicate and mean values of steady-state Cug-bp1 levels are shown.
doi:10.1371/journal.pone.0003968.g005
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Figure 7. Expression of LacZ-(CUG)400 RNAs is insufficient to dysregulate IR and cTNT splicing in human myoblasts. Panel A: DMPK
11-15(CTG)5 or 300 (a), GFP-DMPK 39UTR (CTG)5 or 400 (b) and LacZ-(CTG)0 or 400 (c) cassettes under the transcriptional control of the cytomegalovirus
(CMV) promoter are shown. Panel B: Nuclear DAPI staining of human normal myoblasts expressing DMPK11-15(CTG)5 (a), DMPK 11-15(CTG)300 (b),
GFP-DMPK 39UTR(CTG)5 (c), GFP-DMPK 39UTR(CTG)400 (d), LacZ-(CTG)0 (e), LacZ-(CTG)400 (f) cassettes are shown. The mutant transcripts encoding the
expanded CUG tracts were detected by hybridization with a (CAG)10-Cy3 probe. CUG RNA foci are observed primarily within the nucleus in normal
myoblasts expressing DMPK11-15(CTG)300 (red signal; b) and GFP-DMPK 39UTR (CTG)400 (red signal; d). CUG RNA foci are observed in the cytoplasm
(red signal; f) in normal myoblasts expressing the LacZ-(CTG)400 cassette. Normal myoblasts expressing DMPK11-15(CTG)5 (a), GFP-DMPK 39UTR(CTG)5
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DM1 pathology in mice [24,39]. CUG expansions that are
expressed in a context other than the DMPK 39UTR show more
variable results. Expression of high levels of RNAs encoding ,250
CUG tracts located in the 39UTR of the human skeletal actin gene
cause both intra-nuclear foci and DM1 pathophysiology in mouse
skeletal muscles [37]. In contrast, expression of ,162 CUG
repeats embedded in sequences that contain ,100 bps of DMPK
39UTR sequences in flies showed nuclear foci but no pathology
[40]. In a second study in flies, 480 interrupted CUG tracts
expressed as a non-coding transcript allowed both the develop-
ment of nuclear foci and pathology in several tissues [41]. In a
third study, inducible expression of interrupted CUG tracts,
varying in length from 16 to 480 repeats, was studied in various
transgene insertion contexts in flies. In this set of experiments
several fly strains showed nuclear foci but only one strain of
transgenic flies showed significant pathology [42]. It is currently
unclear why such variability is observed in flies; however CTG
tract sizes, expression levels and context of expression may all
contribute to the differences in the observed phenotypes. These
data demonstrate that although nuclear foci are not sufficient to
produce a DM1 phenotype, in all cases in which DM1 pathology
develops nuclear foci are observed. Thus taken together these data
support the hypothesis that nuclear foci are required for DM1
pathology to manifest, but may not under some circumstances be
sufficient to produce an overt phenotype, when either the CTG
tract length, RNA expression levels, stability or context are less
than optimal.
A noteworthy exception to this rule is the production of a DM1
phenocopy that results from the inducible expression of GFP
sequences linked to the normal DMPK 39UTR in mice [43]. No
foci are observed in this study as the transgene encodes only 5
CTG repeats. Surprisingly, both severe cardiac and skeletal
muscle pathology in conjunction with RNA splice defects are
observed in these animals [43]. However, both our current study
and those of others, demonstrate that expression of similar
transgenes, in which GFP sequences are linked to the normal
DMPK 39UTR, in myoblast cell cultures is insufficient to cause
aberrant RNA splicing or dysregulate myoblast differentiation
[Figure 7, 44]. Thus the precise mechanism that underlies both the
heart and skeletal muscle phenotypes observed in this phenocopy
has yet to be completely understood. As DM1 patients are
characterized by expanded CTG tracts, it is likely that the
mechanistic basis for the pathology observed in this mouse strain
differs in important ways from that observed in DM1 patients.
As noted above, a study by Wang and colleagues demonstrates
that inducible expression of 960 interrupted CUG repeats located
in the DMPK 39UTR sequence results in the development of
nuclear foci concurrent with arrhythmias, cardiomyopathy,
cystolic and diastolic dysfunction and aberrant splicing [24]. In
this study, we examined cardiac specific expression of 400
uninterrupted CUG repeats located in the 39 of the b-galactosidase
gene. In contrast to the results obtained by Wang et al., LacZ-
(CUG)400 RNAs aggregate exclusively in the cytoplasm and do not
result in aberrant splice site selection in several RNAs implicated
in DM1 including Tnnt2, Alp, Zasp and m-Titin [Figure 6].
Consistent with the lack of splicing defects mild cardiac
dysfunction was observed in a-MHC-LacZ-(CTG)400 mice.
Specifically, structural analysis did not demonstrate gross abnor-
malities or hypertrophy. Ultra structural defects in mitochondria
were observed in some sections [Figure 9], however such
abnormalities were not widespread in the a-MHC-LacZ-
(CTG)400 mice. The molecular defects that contribute to the
observed mitochondrial abnormalities are unclear, but may be the
result of modest decreases in Mbnl1 levels or function in the
cytoplasm or alternatively are due to the increased steady-state
Cug-bp1 levels. ECG data obtained in conscious a-MHC-LacZ-
(CTG)400 mice was normal, however sedated a-MHC-LacZ-
(CTG)400 TG
low animals showed increased incidence of intraven-
tricular conduction delay or bundle branch block and a
significantly longer QRS duration [Tables 7 & 8]. Thus, the
infra-Hisian conduction defect in a-MHC-LacZ-(CTG)400 mice
may be subtle and may become unmasked with concomitant
medications which slow conduction, such as anaesthetics. It is
currently unclear why the a-MHC-LacZ-(CTG)400TG
low mice
demonstrate a more severe phenotype than the a-MHC-
LacZ(CTG)400TG
high mice. These differences may reflect the
relatively subtle nature of the pathology and large numbers of mice
in both groups may need to be analyzed to accurately assess
differences in phenotypes that result from varying levels of
transgene expression. These data therefore demonstrate that
cytoplasmic LacZ-CUG foci are relatively benign and are not
sufficient to either dysregulate splicing of a set of RNAs currently
implicated in DM1 or result in significant cardiac pathology in vivo.
As the a-MHC promoter contains two exons and two
intervening introns [28] the lack of transgene RNA splicing is
unlikely to be the reason for the absence of nuclear CUG
aggregation in a-MHC-LacZ-(CTG)400 mice. Intrinsic defects in
the CTG tracts are also unlikely to be responsible for the lack of
toxicity of LacZ-(CUG)400 RNAs, as these repeat sequences
demonstrate marked instability that characterizes uninterrupted
repeat tracts [29,30]. Low steady-state levels of the LacZ-(CUG)400
RNAs could be a feature that influences the relatively benign
phenotype. However, comparable expression levels of LacZ-
(CUG)400 RNAs to that achieved by a DMPK minigene cassette
encoding expanded CTG repeats was not sufficient to dysregulate
splice site choice in human myoblasts cultures [Figure 8].
Therefore, the lack of toxicity of the LacZ-(CUG)400 RNAs could
be either due to the cytoplasmic location of the CUG aggregates or
alternatively to the lack of key regulatory elements in sequences
that flank the repeat. Our data cannot distinguish between these
two possibilities. In this regard it is important to note a study by
Mastroyiannopoulos and colleagues, which demonstrates that
expanded CUG tracts when expressed in the context of the
DMPK 39UTR, aggregate within the nucleus in myoblast cultures
and prevent normal differentiation. Significantly, when this
transgene is engineered to encode the woodchuck post transcrip-
tional element that results in forced localization of the mutant
RNA to the cytoplasm, the toxicity associated with these RNAs
disappears, and they are no longer capable of dysregulating
normal myoblast differentiation [27]. Thus these studies when
taken together support the hypothesis that localization of CUG
repeat RNA within the cytoplasm is an important variable, which
is sufficient to render such RNAs non-toxic both in cell culture
experiments and in the context of the whole animal.
Expression of CUG tracts results in aberrant RNA splicing due
to its effect on a set of alternative splice factors, which include
(c), and LacZ-(CTG)0 (e) constructs did not show RNA foci. Panel C: IR and cTNT RNA splicing in myoblasts expressing the indicated cassettes are
shown. Synthesized cDNAs (150 ng) were subjected to RT-PCR analysis using the IR and cTNT primers described in Methods. GAPDH RNA was
amplified in parallel as an internal control. The experiments were carried out in triplicate. Representative panels are shown in Panel C and the results
are tabulated in Table 4.
doi:10.1371/journal.pone.0003968.g007
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Figure 8. Quantitation of the steady-state levels of LacZ-(CUG)400 and DMPK 11-15(CUG)300 RNAs. Panels A–B: RT-PCR analyses of the
steady-state expression levels of LacZ-(CTG)0, LacZ-(CTG)400, and DMPK11-15(CTG)5, DMPK 11-15(CTG)300 cassettes are shown. Synthesized cDNA
(100 ng) from normal myoblsts expressing LacZ-(CTG)0 or 400 and DMPK 11-15(CTG)5 or 300 were subjected to RT-PCR analysis. GAPDH RNA was
amplified in parallel as an internal control. The experiments were carried out in triplicate and the results are tabulated in Table 5. Relative steady-
state expression levels of the LacZ-(CTG)400 and DMPK 11-15(CTG)300 cassettes were not significantly different (p = 0.479). Panels C–F: Real-time PCR
analysis of serial dilutions of plasmid DNAs encoding LacZ-(CTG)400 and DMPK 11-15(CTG)300 sequences and of LacZ-(CTG)400 and DMPK 11-
15(CTG)300 cDNAs is shown. PCR reactions were carried using 10
22 to 1026 fmoles of plasmid DNAs encoding LacZ-(CTG)400 or DMPK 11-15(CTG)300
sequences. To quantitate the expression levels of expanded CUG repeat encoding transcripts, cDNAs (5 ng) from human myoblasts expressing LacZ-
(CTG)400 and DMPK 11-15(CTG)300 were subjected to Real-time PCR analysis in parallel. LacZ-(CTG)400 and DMPK 11-15(CTG)300 cDNAs are present at
approximately similar levels (Panels C, E & Table 6). Melting curves of LacZ-(CTG)400 or DMPK 11-15(CTG)300 PCR reactions are shown (Panels D &
F). GAPDH was used as an internal control for RNA quality and the reverse transcriptase reaction (Ct values for GAPDH in LacZ-(CTG)400 and DMPK 11-
15(CTG)300 samples was 19.8 in each case).
doi:10.1371/journal.pone.0003968.g008
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MBNL1 and CUG-BP1 [25,26,32,33,39,45–49]. Specifically,
expression of expanded CUG repeat sequences results in elevated
steady-state CUG-BP1 protein levels, which plays a causative role
in dysregulating splice site choice in a set of physiologically
important RNAs implicated in DM1 both in cell culture and
transgenic mouse experiments [25,33,39,45–49]. However, our
previous results in DM1 myoblasts demonstrate that siRNA
mediated reduction of CUG-BP1 levels does not correct aberrant
IR splicing [46,47]. Thus these results demonstrate that although
increased steady state levels of CUG-BP1 is sufficient to produce
features of DM1, elevated CUG-BP1 levels may not be required
for DM1 pathology to manifest, as reduction of CUG-BP1 levels
does not correct the splice defects in DM1 myoblasts.
Table 4. Aberrant RNA splicing results from the expression of expanded CTG repeats in myoblasts.
Gene
Alt. spliced exon
number n
DMPK 11-
15(CTG)5
DMPK 11-
15(CTG)300
% Exons splicing
Normal
myoblasts
DM1
myoblasts
GFP-DMPK
39UTR(CTG)5
GFP-DMPK
39UTR(CTG)400
LacZ-
(CTG)0
LacZ-
(CTG)400
IR 11 3 52.462.3 6.261.7* 51.462.7 11.262.3* 43.763.5 46.962.9 46.762.7 6.263.1*
cTNT 5 3 30.561.9 83.962.6* 32.562.9 81.663.1* 27.361.8 30.162.3 ND ND
Asterisk (*) represents significant differences from the control (Student’s t-test; p,0.05). IR, insulin receptor; cTNT, cardiac troponin T; ND, Not determined.
doi:10.1371/journal.pone.0003968.t004
Table 5. Quantitation of levels of LacZ-(CUG)400 and DMPK 11-15(CUG)300 RNAs by RT-PCR.
Plasmid constructs transfected into myoblasts Relative expression (%) p-value
LacZ-(CTG)0 100.0
LacZ-(CTG)400 85.367.4#
DMPK 11-15(CTG)5 86.569.3
DMPK 11-15(CTG)300 76.467.5# 0.479
(#) represents pair wise comparison; p-value (Student’s t-test) denotes no significant difference in the expression levels of LacZ-(CTG)400 and DMPK 11-15(CTG)300
cDNAs.
doi:10.1371/journal.pone.0003968.t005
Table 6. Quantitation of LacZ-(CUG)400 and DMPK 11-
15(CUG)300 RNAs by Real-time PCR.
cDNA fmole p-value
LacZ-(CTG)400 5.68610
24
DMPK 11-15(CTG)300 4.17610
24 0.06
p-value (Student’s t-test; p,0.05) denotes no significant difference in the levels
of LacZ-(CTG)400 and DMPK 11-15(CTG)300 cDNAs.
doi:10.1371/journal.pone.0003968.t006
Table 7. Telemetry measurements in conscious a-MHC-LacZ-
(CTG)400 mice.
LacZ (N=5)
TGhigh
(N=14)
TGlow
(N=9)
One-way
ANOVA
SCL (ms) 9965 8869 8868 ns (0.06)
HR (bpm) 609631 685671 686659 ns (0.06)
PR (ms) 35.461.8* 31.962.1* 33.462.3 p= 0.011
QRS (ms) 14.660.7 14.061.5 14.861.0 ns
QT (ms) 24.861.5 23.462.3 25.262.9 ns
QTc (ms) 25.061.2 25.062.7 26.862.7 ns
Parameter values represent mean6standard deviation. Matching symbols (*)
denote significant differences between groups in post hoc testing for that
parameter; LacZ, a-MHC-LacZ-(CTG)0; TG
high, a-MHC-LacZ-(CTG)400TG
high; TGlow,
a-MHC-LacZ-(CTG)400TG
low; SCL, sinus-cycle length; HR, heart rate; PR, atrial and
A–V nodal conduction time; QRS, ventricular depolarization time; QT, surrogate
of action potential duration; QTc, corrected surrogate of action potential
duration; ms, milliseconds, bpm, beats per minute.
doi:10.1371/journal.pone.0003968.t007
Table 8. ECG measurements in sedated a-MHC-LacZ-(CTG)400
mice.
LacZ (N=5)
TGhigh
(N=14) TGlow (N=9)
One-way
ANOVA
SCL (ms) 14763 143619 14267 ns
HR (bpm) 40768 427656 424620 ns
PR (ms) 39.662.8 37.363.4 41.265.5 ns
QRS (ms) 13.960.8 13.762.5* 16.861.8* P= 0.005
QT (ms) 24.561.2# 22.663.7* 30.062.9*# P#0.001
QTc (ms) 20.260.9# 19.164.0* 25.262.5*# P#0.001
Parameter values represent mean6standard deviation; Matching symbols (*,#)
denote significant differences between groups in post hoc testing for that
parameter; LacZ, a-MHC-LacZ-(CTG)0; TG
high, a-MHC-LacZ-(CTG)400TG
high; TGlow,
a-MHC-LacZ-(CTG)400TG
low; SCL, sinus-cycle length; HR, heart rate; PR, atrial and
A–V nodal conduction time; QRS, ventricular depolarization time; QT, surrogate
of action potential duration; QTc, corrected surrogate of action potential
duration; ms, milliseconds, bpm, beats per minute.’’
doi:10.1371/journal.pone.0003968.t008
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Inactivation of MBNL1 plays an important role in etiology of
DM1 spliceopathy. Specifically, disruption of Mbnl1 in mice is
sufficient to recapitulate key features of the disease [32]. We have
shown that re-expression of MBNL1 is sufficient to rescue the IR
splice defects in DM1 patient cells [46,47]. Consistent with our
results, over expression of MBNL1 in transgenic mice expressing
CTG tracts allows the rescue of both the splice defects and myotonia
[50]. These data therefore demonstrate first, that functional
inactivation of MBNL1 is sufficient to produce DM1 pathophysi-
ology. Second, as MBNL1 mediated rescue serves to correct key
features of DM1, inactivation of MBNL1 must be a necessary event
that is required for the development of DM1 pathophysiology. The
mechanism of MBNL1 inactivation is currently unknown. As
previous studies have shown marked sequestration of MBNL1 in
CUG foci both in skeletal muscle and heart cells (35,36), it has been
hypothesized that MBNL1 depletion occurring as a consequence of
aberrant sequestration, is a key mechanism that underlies the
functional inactivation of MBNL1 in DM1.
As splice defects are not observed in a-MHC-LacZ-(CTG)400
mice, we studied the ability of the LacZ-(CUG)400 RNA to alter
the stoichiometry or behavior of Mbnl1 and Cug-bp1. Similar, but
relatively small amounts of endogenous MBNL1, localize both in
nuclear CUG foci (,8%) in DM1 myoblasts, where aberrant
splicing is observed, and in cytoplasmic CUG-foci (,7%) in a-
MHC-LacZ-(CTG)400 cardiomyocytes, where splice defects are
not observed [Figure 4]. As experiments in Mbnl1+/2 mice
demonstrate that an ,50% decrease in Mbnl1 is insufficient to
alter splice site choice [32], these data demonstrate that
aggregation per se cannot be the sole mechanism that underlies
MBNL1 inactivation in DM1 cells. Nonetheless, MBNL1
inactivation must be a key event in DM1 myoblasts as over
expression of MBNL1 is sufficient to rescue the splice defects in
these cells [46,47]. Thus as expression of LacZ-(CUG)400 RNAs is
not sufficient to dysregulate RNA splicing, these RNAs must also
by inference be unable to inactivate Mbnl1 function in vivo. The
molecular basis of MBNL1 inactivation in DM1 myoblasts is
currently unclear and is an important area of future investigation.
Significantly, steady state Cug-bp1 levels are elevated ,2.4 and
,1.5 fold in a-MHC-LacZ- (CTG)400TGhigh and a-MHC-LacZ-
(CTG)400TG
low mice respectively, at six months of age [Figure 5].
Experiments carried out by Lin and colleagues demonstrate that
expression of ,250 CTG repeats located in the 39UTR of a-actin
gene does not result in elevated Cug-bp1 levels in mouse skeletal
muscles [35]. These data demonstrate that CTG tracts, greater
than 250 repeats, may be necessary to increase steady state Cug-
bp1 levels, in adult mouse tissues. On inducible expression of very
high levels of interrupted CTG tracts, Cug-bp1 levels are
increased in the heart [24]. However as Cug-bp1 levels were not
quantitated in this study, the exact increases in Cug-bp1 levels at
time points at which splice defects manifest are unclear. Cug-bp1
over expression studies in mice demonstrate that a 4–6 fold
elevation in Cug-bp1 levels [48] may be required to result in
aberrant splicing. Therefore, in adult mouse tissues very high
levels of Cug-bp1 may be necessary to elicit splice defects. If adult
human tissues behave in a similar fashion, CUG-BP1 levels, which
are high enough to dysregulate splicing, may result only in
conjunction with the expression of very large CTG tracts. In this
event, elevated CUG-BP1 levels may be more relevant in the
etiology of congenital DM1 rather than adult onset DM1.
Our results show that CTG tracts are necessary but not
sufficient to cause nuclear aggregation of CUG repeats. The
precise RNA motifs required for nuclear aggregation of CUG
repeats are currently unknown; however, the presence of such
motifs must play a key role both in determining the ultimate
location of the CUG repeat encoding RNAs. In this respect it is
significant to note that both MBNL1 and hnRNP H have been
shown to be required for nuclear focus formation [46,51].
Specifically, we have shown that siRNA mediated inactivation of
MBNL1, which binds to the stem of the CUG hairpin, results in
increased dispersion of nuclear foci in DM1 cells [46]. siRNA
mediated reduction of hnRNP H, which binds to the base of the
CUG hairpin, has also been demonstrated to allow transport of
RNAs encoding expanded CUG repeats into the cytoplasm [51].
These results suggest that proteins that either bind to CUG
hairpins or to key regions of the flanking sequence may facilitate
hairpin stabilization and aggregate formation in the nucleus. As
aggregation and transport into the cytoplasm may be two
competing events within the nucleus, these data predict that small
molecules, which serve to decrease the rate of aggregate formation
in the nucleus, to allow transport of the toxic CUG RNAs into the
cytoplasm, may be sufficient to greatly ameliorate DM1 symptoms
in patients whose repeat tract sizes are not long enough to elicit
large increases in CUG-BP1 levels. Thus small molecules that
decrease the rate of either MBNL1 or hnRNP H binding to the
mutant DMPK RNA may serve to increase its transport out of the
nucleus. Such a cadre of drugs is attractive as they may prove to be
less toxic, when compared to small molecules that abolish the
interaction of these proteins with the mutant DMPK RNA, as their
disruptive effect on MBNL1 or hnRNP H interactions with their
normal target RNAs may be less severe.
Materials and Methods
Cell culture and transfection
Normal and DM1 myoblasts were a generous gift from Dr.
Charles Thornton. DM1 fibroblasts were purchased from Coriell
Figure 9. Aberrant mitochondrial cristae are observed in a-MHC-LacZ-(CTG)400 hearts. Electron micrographs of adult heart sections of a-
MHC-LacZ (A) and a-MHC-LacZ-(CTG)400TG
high (B) mice are shown. Mitochondrial cristae were disarrayed in a subset of sections viewed.
doi:10.1371/journal.pone.0003968.g009
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Institute for Medical Research, NJ, U.S.A. Normal and DM1
myoblast and fibroblasts cultures were immortalized by infection
with the SV40 virus. Myoblast cultures and lines were
maintained in SKGM medium (Lonza Inc., USA) containing
10% fetal bovine serum and fibroblast cultures and lines were
maintained in MEM medium containing 20% fetal bovine
serum.
FISH analyses
In situ fluorescence hybridization (FISH) analyses were carried
out primarily as described by Taneja et al, 1995 [15] and
Dansithong et al, 2005 [46]. Briefly, cardiomyocytes were
prepared from mouse hearts using standard protocols [52] and
plated immediately on chamber slides and fixed in 4%
paraformaldehyde in PBS for 20 minutes at room temperature
and stored in 70% ethanol at 4uC. Endogenous MBNL1 was
detected using MBNL1 monoclonal antibody (MB1a) at a dilution
of 1:200 [31]. Secondary antibody, anti-mouse IgG conjugated
with FITC (Alexa Fluor 488, Molecular probes, USA) was used at
a dilution 1:2000. For FISH studies, a Cy3 conjugated (CAG)10
oligonucleotide probe (Operon, USA) was used to detect CUG
repeat expansions as described by Taneja et al, 1995 [15]. To
estimate the amount of MBNL1 present in the nucleus, the
cytoplasm and the foci, the fluorescence signals (area6intensity)
were measured using IP Lab software (Scanalytics Inc., USA). The
percentage of MBNL1 present in the nucleus and cytoplasm of
cardiomyocytes derived from a-MHC-LacZ mice and normal
human myoblasts was calculated as: MBNL1nucleus = [MBNL1nu-
cleus/MBNL1whole cell]6100; MBNL1cytoplasm = [(MBNL1whole cell2
tMBNL1nucleus)/MBNL1whole cell]6100. For cardiomyocytes derived
from a-MHC-LacZ-(CTG)400 mice the percentage of MBNL1 in
nucleus, cytoplasm and foci was calculated as: MBNL1nucleus =
[MBNL1nucleus/MBNL1whole cell]6100; MBNL1cytoplasm =
[(MBNL1whole cellt2(MBNL1nucleus+MBNL1cytoplasmic foci)/
MBNL1whole cell]6100 ; MBNL1 cytoplasmic foci = MBNL1cytoplas-
mic foci/MBNL1whole cell6100. In DM1 myoblasts the percentage
of MBNL1 in nucleus, cytoplasm and foci was calculated as:
MBNL1nucleus = [MBNL1nucleus2MBNL1nuclear foci/MBNL1whole
cell]6100; MBNL1cytoplasm = [(MBNL1whole cell2(MBNL1nu-
cleus+MBNL1 nuclear and cytoplasmic foci)/MBNL1whole cell]6100;
MBNL1nuclear and cytoplasmic foci = MBNL1nuclear and cytoplasmic foci/
MBNL1whole cell6100. FISH was performed on frozen sections
(6 mm) using (CAG)10-Cy3 probes as described by Mankodi et
al, 2000 [37]. After hybridization, the sections were mounted
with mounting medium (Vector, USA). In all cases the images
were examined using a LSM 510 Confocal microscopy in the
Doheny Eye Institute at the University of Southern California.
Generation of a-MHC-LacZ-(CTG)400 and a-MHC-LacZ
mice
(CTG)400 tracts were cloned into an SfiI site located within a
linker sequence (TGGCCACGCGGGCCATTTAAATGGC-
CATTAGGGCC: SfiI sites are underlined) that was inserted between
the termination codon of the b-galactosidase gene and the bovine growth
hormone polyadenylation (BGH-PolyA) sequence. The a-myosin heavy chain
(a-MHC) promoter was used to drive expression of the transgene [28]. Both
the a-MHC-LacZ-(CTG)400 cassette and control a-MHC-LacZ cassette,
which did not encode an expanded CTG tract were injected into fertilized
C57BL/6J mouse eggs to generate two a-MHC-LacZ-(CTG)400 lines and
two control a-MHC-LacZ lines [a-MHC-LacZ-(CTG)0]. The transgenic
mice were genotyped by PCR using b-galactosidase specific primers (forward
59-ATGATAGATCCCGTCGTTTT ACAAC-39 and reverse 59-
TCAATCAGCGTGCCGTCG GCGGTG-39).
Southern and Northern blot analyses
For Southern blot analyses, genomic DNA from transgenic mice
tails was digested with PvuII and for Northern blot analyses, total
RNA from transgenic heart tissue was isolated using Trizole
(Invitrogen, USA) according to the manufacturer’s protocol. The
blots were hybridized with radioactive probes using standard
techniques. The probe used for Southern blot analyses consists of a
280 bp fragment of the BGH-PolyA sequence shown in Figure 2;
Panel A. b-galactosidase (bases 300–815) and Gapdh specific probes
were used to detect transcripts in Northern blot analyses.
Western blot analyses
Heart tissue was collected from transgenic mice and extracts
were prepared by homogenization with the extraction buffer
[25 mM Tris-HCl pH 7.6, 400 mM NaCl, 0.5% NP40, 5 mM
EDTA, 25% Sucrose, 2 mM PMSF and Protease inhibitor (Sigma
Inc., Catalog# P-8340)]. Tissue extracts were incubated on ice for
1 hour and then centrifuged for 20 min at 20,0006g. Equal
amounts of protein (either 6 mg or 10 mg) were resolved by SDS-
PAGE and transferred to Hybond P membranes (Amersham
Bioscience Inc., USA). After blocking with 5% skim milk in 0.1%
Tween 20 in PBS, the membranes were incubated with primary
antibodies for 2 hrs at room temperature or overnight at 4uC. The
membranes were washed with 0.1% Tween 20 in PBS and
subsequently incubated with the corresponding secondary anti-
bodies conjugated with HRP. Signals were detected by using the
ECL plus detection reagents (Amersham Bioscience Inc., USA)
according to the manufacturer’s protocol. The primary antibodies
were CUG-BP1 [3B1 monoclonal antibody (200 mg/ml), Santa
Cruz Inc. (catalog # sc-20003), 1:4000], and MBNL1 monoclonal
antibody (MB1a, 1:3000) [31] to detect the Cug-bp1 and Mbnl1.
To control for protein quality and loading the membranes were re-
probed with goat anti-GAPDH [V-18 polyclonal antibodies
(200 mg/ml), Santa Cruz Inc. (catalog # sc-20357)] at a dilution
of 1:3000. The secondary antibody dilutions were 1:8000 for goat
anti-mouse IgG-HRP [(1 mg/ml), Sigma Inc. (catalog # A2304)],
and 1:5000 for donkey anti-goat IgG-HRP [(400 mg/ml), Santa
Cruz Inc. (catalog # sc-2056)]. The relative band intensities were
measured by densitometry analyses using Gene Tool (Syngene
Inc., USA). To ensure that the signals were not saturated, prior
standardization experiments were carried out as described in Paul
et al, 2006 [47].
Sub-cellular fractions (cytoplasmic and nuclear) from mouse
heart tissue was prepared using methods primarily described by
Charlet et al, 2002 [49] with some modifications. Heart tissues
were collected from transgenic mice and homogenized with cold
lysis buffer (25 mM Tris–HCl [pH 7.6], 10 mM NaCl, 1.0 mM
EDTA, 2.0 mM MgCl2, 0.5 mM DTT, and protease inhibitor).
The soluble fraction was passed through a 26-gauge needle eight
times using a 1 ml syringe. Nuclear: cytoplasmic separations were
carried out by centrifugation twice at 6006g for 5 min. The
cytoplasmic extract was prepared by centrifuging the supernatant
fraction for 20 min at 20,0006g. The pellet from the nuclear:
cytoplasmic separations was suspended in nuclear extraction
buffer (25 mM Tris–HCl [pH 7.6], 600 mM NaCl, 0.05%
NP40, 1.0 mM EDTA, 2.0 mM MgCl2, 0.5 mM DTT, and
protease inhibitor) and centrifuged for 20 min at 20,0006g. The
resulting supernatant was denoted as a nuclear extract. Equal
amounts of protein (10 mg) from the nuclear and cytoplasmic
fractions were resolved by SDS-PAGE and transferred to Hybond
P membranes. The membranes were probed with TBP (TATA
binding protein) monoclonal antibody [(1.99 mg/ml), Abcam Inc.
(catalog # ab818), 1:5000], which was used as a nuclear marker
and goat anti-GAPDH [V-18 polyclonal antibodies (200 mg/ml),
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Santa Cruz Inc. (catalog # sc-20357), 1:3000], which was used as
a cytoplasmic marker. The secondary antibody dilutions were
1:8000 for goat anti-mouse IgG-HRP [(1 mg/ml), Sigma Inc.
(catalog # A2304)], and 1:5000 for donkey anti-goat IgG-HRP
[(400 mg/ml), Santa Cruz Inc. (catalog # sc-2056)].
RT-PCR analyses of RNA isolated from transgenic mice
Total RNA was isolated from transgenic mouse hearts using
Trizole (Invitrogen, USA) according to the manufacturer’s
protocol. cDNA was synthesized from 5 mg of total RNA using
the cDNA synthesis kit (Amersham Bioscience Inc., USA) and
PCR was carried out using 150 ng of the synthesized cDNA. PCR
amplification was carried out for 25 and 30 cycles for each gene.
The sequences of the primers used for the amplification of Tnnt2,
Alp, Zasp, and m-Ttn are: Tnnt2 (forward 59-GCCGAG-
GAGGTGGTGGAGGAGTA-39, reverse 59-G TCTCAGCCT-
CACCCTCAG GCTCA-39), Alp (forward 59-AGCTGCCAA
tCCTGTGTCCTG-39, reverse 59-GATCCTGCAGCACCCT-
GAAG-39), Zasp (forward 59-GGAAGATGAGGCTGATGAGT
GG-39, reverse 59-TGCTGACAGTGGTAGTGCT CTTTC-39),
and m-Ttn (forward 59-GTGTGAGTCGCTCCAGAAACG-39
reverse 59-CCACCACAGG ACCATGTTATTTC-39). To en-
sure that the signals were not saturated, prior standardization
experiments were carried out as described in Paul et al, 2006 [47].
The PCR products were cloned and verified by sequencing. The
relative band intensities were measured by densitometry analyses
using Gene Tool. Percent of exon inclusion was calculated as
[exon inclusion/(exon inclusion+exon exclusion)]6100.
Construction of CTG expression plasmids
DMPK 11-15(CTG)5 or 300 plasmids encoding DMPK exons 11-
15 (2.3 kb), containing either 5 CTG repeats or 300 interrupted
CTG repeats in exon 15, was cloned into pAdTrac-CMV (ATCC,
USA) using techniques described by Philips et al, 1998 [33]. The
interrupted repeats are composed of repeating units of the
sequence (CTG)20CTCGA. The GFP-DMPK 39UTR(CTG)5
plasmid was constructed by cloning a 0.7 kb sequence located
immediately 39 of the human DMPK termination codon, 39 of the
GFP sequences in pEGFP-C1 (BD Clontech, USA). GFP-DMPK
39UTR(CTG)400 was constructed by cloning an uninterrupted
tract of ,400 CTG repeats at the site of the existing (CTG)5
repeat sequence in the GFP-DMPK 39UTR(CTG)5 plasmid. The
LacZ-(CTG)0 or 400 plasmids were constructed by cloning cassettes
encoding the b-galactosidase gene followed by a tract of either 0 or
,400 uninterrupted CTG repeats and the BGH-PolyA sequence
at 39 of the CMV promoter in pcDNA3.1 [Invitrogen, USA]. The
integrity of the CTG repeats was confirmed by restriction enzyme
analysis and sequencing.
RT-PCR and Real-time PCR analyses of RNA isolated from
human myoblasts
Normal myoblasts were transfected with 6 different cassettes
under the transcriptional control of the CMV promoter as
described previously [46]. Briefly, the transfected cells were
selected by treating with G418 (300 mg/ml) for 5 days. Total
RNA was isolated using the RNAeasy mini kit (Qiagen Inc., USA)
according to the manufacturer’s protocol. DNAse I treated RNAs
were used to synthesize cDNA using MMLV reverse transcriptase
and random hexanucleotide primers. PCR analyses were carried
out as described above. The sequences of the primers used for the
amplification of insulin receptor (IR), cardiac troponin T (cTNT)
and GAPDH RNAs are: IR (forward 59-CCAAAGACAGACTCT-
CAGAT-39, reverse 59-AACATCGCCAAGGGACCTGC-39),
cTNT (forward 59-ATAGAAGAGGTGGTGGAAGA GTAC-39,
reverse 59-GTCTCAGCCTCTGCTTCAGCATCC-39), GAPDH
(forward 59-TGAAGGTCG GAGTCAACGGATTTGG-39, re-
verse 59-GGAGGCCATGTGGGCCATGAG-39). To assess the
steady-state expression levels of the b-galactosidase gene and
DMPK minigene encoding expanded CTG tracts, synthesized
cDNA (100 ng) from normal myoblasts expressing LacZ-(CTG)0 or
400 and DMPK 11-15(CTG)5 or 300 were subjected to RT-PCR
analysis. The primers sequences used for the amplification of
LacZ-(CTG)0 or 400 and DMPK 11-15(CTG)5 or 300 are: LacZ-
(CTG) 0 or 400 constructs (forward 59-ATGAT AGATCCCGTCG
TTTTACAAC-39 and reverse 59-TCAATCAGCGTGCCGTCG
GCGGTG-39) and DMPK 11-15(CTG)5 or 300 constructs (forward
59-GAAGGCAGCAAGCCGGGCCGTCCG-39, reverse 59-AG
GGGGAGGTGTGGGAGGTTTTTT-39). GAPDH was ampli-
fied in parallel as an internal control for RNA quality and the
reverse transcriptase reaction. The relative band intensities were
measured by densitometry analyses using Gene Tool. To ensure
that the signals were not saturated, prior standardization
experiments were carried out as described in Paul et al, 2006
[47]. Signals were normalized to the expression of GAPDH and
tabulated as percent relative expression. Real-time PCR was
carried out to quantitate the expression levels of LacZ-(CUG)400
and DMPK 11-15(CUG)300 transcripts. The primers used in Real-
time PCR are: LacZ-(CTG)400 constructs (forward 59-ATGATAG
ATCCCGTCGTTTTAC-39, reverse 59-CGCCATTCAGGCT
GCGCAACTGTTG-39), DMPK 11-15(CTG)300 constructs (for-
ward 59-GAATGCACTGAGACCCCGACATTCC-39, reverse
59-ATTATGA TCAGTTATCTAGATCCGG-39), and GAPDH
(forward 59-CCACCCATGGCAAATTCCATG-39, reverse 59-
TGATGGGATTTCCATTGATGAC-39). The PCR reaction
mixture contained SYBR Green PCR Master Mix (Bio Rad
Inc., USA) and 0.5 pmol primers. PCR amplification was carried
out for 45 cycles: denaturation at 95uC for 30 sec, annealing at
60uC for 30 sec and extension at 72uC for 1 min.
Electrocardiography Studies
A total of 35 adult C57BL/6J strain mice were studied. The
mean age was 2768 weeks and mean weight was 3065 grams of
all mice. Mice were anesthetized with intraperitoneal pentobar-
bital (0.033 mg/gm each). A 6-lead surface ECG was obtained
with 25 gauge electrodes placed subcutaneously in each limb.
Mean sinus-cycle length (SCL), heart rate (HR), PR, QRS, and
QT intervals were measured for each animal as described by Berul
et al, 1996 [53]. A rate corrected QT interval (QTc) was
calculated using a murine formula [54].
Ambulatory Electrocardiogram Telemetry
Radiofrequency transmitters (DataSciences International, St.
Paul, MN, USA) were implanted into a subcutaneous pocket with
leads secured under the upper right and left limbs to record lead I
ECG. After a 48-hours recovery period, ECGs were recorded
continuously for 10 minutes. All baseline telemetry measurements
for SCL, PR, QRS and QT intervals were made for three
consecutive cardiac cycles by an experienced observer blinded to
the genotypes of the mice.
Exercise Tolerance Test
Animals with implanted transmitters were exercised on a
multilane graded treadmill machine (Exer-6M, Columbus Instru-
ments, Columbus, OH, USA). Mice were encouraged to run for
30 minutes at a constant speed of 12.5 m/min at a slope of
15 degrees. Telemetry ECG recordings and measurements were
made at rest, after 10 and 20 minutes of exercise, just before
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termination of exercise, and at recovery. During exercise and
recovery, telemetric ECG recordings were examined for conduc-
tion abnormalities and the presence of inducible arrhythmias.
Statistical Analysis
Statistical analyses were performed with SPSS software version
11.5 for Windows. Continuous variables, such as ECG intervals,
cardiac conduction properties and echocardiography measure-
ments were compared for genotypes using an analysis of variances
(ANOVA) test followed by post-hoc analysis. Pearson chi-square
tests were performed for categorical data. Values are presented as
the mean61 standard error of mean (SEM). The Student t-test
was used to analyze data derived from RNA splicing, expression
analyses and the examination of MBNL1 cellular localization.
Statistical significance was established with a p value of ,0.05.
Supporting Information
Figure S1 Images of DM1 cells containing both nuclear and
cytoplasmic foci. Panels A–E: Nuclear DAPI stains of normal and
DM1 myoblast and fibroblast cultures and SV40 transformed lines
are shown in the upper set of panels. Mutant DMPK transcripts
encoding the expanded CUG tracts are detected by hybridization
with a (CAG)10-Cy3 probe (middle panels). The lower set of
panels show merged images of DAPI and (CAG)10-Cy3 stains,
demonstrating the nuclear and cytoplasmic location of the CUG
RNA foci in these cells. Transcripts containing expanded CUG
repeats are not observed in the normal myoblasts and fibroblasts.
In DM1 cells, ,70% and ,30% of all sampled cells [number of
cells counted in each case are shown in Figure 1; Table 1 of the
main text] showed nuclear foci or both nuclear and cytoplasmic
foci, respectively.
Found at: doi:10.1371/journal.pone.0003968.s001 (2.66 MB TIF)
Figure S2 MBNL1 monoclonal antibody (MB1a) specifically
detects Mbnl1 in mouse cardiomyocytes. Nuclear DAPI stains of
cardiomyocytes derived from wild type, and Mbnl12/2 mice (a
gift from Dr. Swanson MS) are shown in a and c. Distribution of
endogenous Mbnl1 is visualized as a green signal in wild type
cardiomyocytes (b) using anti-MBNL1 (MB1a) monoclonal
antibody and a secondary antibody (anti-mouse IgG) conjugated
with FITC. Mbnl1 is not detected in Mbnl12/2 cardiomyocytes
(d).
Found at: doi:10.1371/journal.pone.0003968.s002 (3.93 MB TIF)
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